{"id":1074,"date":"2022-08-21T20:49:32","date_gmt":"2022-08-21T17:49:32","guid":{"rendered":"https:\/\/sites.uef.fi\/drug-targeting\/?page_id=1074"},"modified":"2023-12-23T10:44:40","modified_gmt":"2023-12-23T08:44:40","slug":"lat1","status":"publish","type":"page","link":"https:\/\/sites.uef.fi\/drug-targeting\/transporters\/lat1\/","title":{"rendered":"LAT1"},"content":{"rendered":"\n<p><strong>L-Type Amino Acid Transporter 1 (LAT1)<\/strong> is a pH and sodium independent antiporter. This heterodimeric protein complex is an essential carrier of large, neutral, aromatic, or branched L-amino acids (e.g., L-Leu, L-Phe, L-Tyr, L-Trp, L-His, L-Met, L-Ile, and L-Val) and some amino acid mimicking drugs (e.g., L-dopa, gabapentin, baclofen, and melphalan). LAT1 consists of a light chain (SLC7A5) and a CD98 heavy chain (4F2hc; SLC3A2), which are linked together via a disulfide bond. The exact role of CD98 is not fully understood, but it has been proposed that it chaperones the complex\u2019s localization to the cell membrane and affects the LAT1\u2019s transportation activity.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"566\" src=\"https:\/\/sites.uef.fi\/drug-targeting\/wp-content\/uploads\/sites\/59\/2022\/12\/Graphical-Abstract-1024x566.png\" alt=\"\" class=\"wp-image-1296\" style=\"width:617px;height:auto\" srcset=\"https:\/\/sites.uef.fi\/drug-targeting\/wp-content\/uploads\/sites\/59\/2022\/12\/Graphical-Abstract-1024x566.png 1024w, https:\/\/sites.uef.fi\/drug-targeting\/wp-content\/uploads\/sites\/59\/2022\/12\/Graphical-Abstract-300x166.png 300w, https:\/\/sites.uef.fi\/drug-targeting\/wp-content\/uploads\/sites\/59\/2022\/12\/Graphical-Abstract-768x425.png 768w, https:\/\/sites.uef.fi\/drug-targeting\/wp-content\/uploads\/sites\/59\/2022\/12\/Graphical-Abstract-1536x849.png 1536w, https:\/\/sites.uef.fi\/drug-targeting\/wp-content\/uploads\/sites\/59\/2022\/12\/Graphical-Abstract-2048x1132.png 2048w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>LAT1 is distributed throughout the body, and it is highly expressed in tissues that require a high amino acid supply, such as the brain and placenta, but it is also found to a lesser extent in other tissues. Moreover, LAT1 is needed to meet the increased demand for amino acids in proliferating cancer cells, and therefore, it is upregulated in various types of tumors. Similarly, certain immune cells have the ability to upregulate LAT1 expression on their cell surface upon their activation. The protein complex is found mainly in the basolateral membrane of polarized epithelia with an exception of the blood-brain barrier (BBB), where it is localized on both luminal and abluminal sides. It has also been found that ubiquitylation of LAT1\u2019s N-terminal tail induces its endocytosis and degradation. Moreover, it has been demonstrated that the lysosomal protein, LAPTM4b, can recruit LAT1 to lysosomes.<\/p>\n\n\n\n<p>We have extensively studied LAT1 as a potential carrier and target of novel drugs.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"608\" height=\"430\" src=\"https:\/\/sites.uef.fi\/drug-targeting\/wp-content\/uploads\/sites\/59\/2023\/12\/Graphical-abstract.jpg\" alt=\"\" class=\"wp-image-2093\" style=\"width:565px;height:auto\" srcset=\"https:\/\/sites.uef.fi\/drug-targeting\/wp-content\/uploads\/sites\/59\/2023\/12\/Graphical-abstract.jpg 608w, https:\/\/sites.uef.fi\/drug-targeting\/wp-content\/uploads\/sites\/59\/2023\/12\/Graphical-abstract-300x212.jpg 300w\" sizes=\"auto, (max-width: 608px) 100vw, 608px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Selected Publications<\/h2>\n\n\n\n<p>Bahrami, K.; J\u00e4rvinen, J.; Laitinen, T.; Reinisalo, M.; Honkakoski, P.; Poso, A.; Huttunen, K. M.; Rautio, J. Structural features affecting selectivity of LAT1-targeted phenylalanine drug conjugates. <strong><em>Molecular Pharmaceutics<\/em><\/strong>, <strong>2022<\/strong>, <em>20<\/em>(1):206-218. <a href=\"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.2c00594\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/doi.org\/10.1021\/acs.molpharmaceut.2c00594<\/a><\/p>\n\n\n\n<p>Huttunen, J.; Agami, M.; Tampio, J.; Montaser, A. B.; Huttunen, K. M. Comparison of Experimental Strategies to Study L-Type Amino Acid Transporter 1 (LAT1) Utilization by Ligands. <strong><em>Molecules<\/em><\/strong>, <strong>2021<\/strong>, <em>27<\/em>(1), 37, 37-57. <a href=\"https:\/\/doi.org\/10.3390\/molecules27010037\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/doi.org\/10.3390\/molecules27010037<\/a><\/p>\n\n\n\n<p>Jalkanen, A.; Ihalainen, J.; Lehtonen, M.; Forsberg, M. M.; Rautio, J.; Huttunen, K. M.; Gynther, M. Species differences between mice and rats in the pharmacology of a LAT1-utilizing compound. <em><strong>International Journal of Pharmaceutics<\/strong><\/em>, <strong>2021<\/strong>, <em>596<\/em>: 120300.&nbsp;<a href=\"https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120300\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120300<\/a><\/p>\n\n\n\n<p>K\u00e4rkk\u00e4inen, J.; Laitinen, T.; Markowicz-Piasecka, M.; Montaser, A.; Lehtonen, M.; Rautio, J.; Gynther, M.; Poso, A.; Huttunen, K.M. Molecular characteristics supporting l-Type amino acid transporter 1 (LAT1)-mediated translocation. <em><strong>Bioorganic Chemistry<\/strong><\/em>, <strong>2021<\/strong>, 112: 104921. <a href=\"https:\/\/doi.org\/10.1016\/j.bioorg.2021.104921\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/doi.org\/10.1016\/j.bioorg.2021.104921<\/a><\/p>\n\n\n\n<p>Huttunen J.; Gynther, M.; Vellonen, K.-S.; Huttunen, K. M. L-Type Amino Acid Transporter 1 (LAT1)-Utilizing Prodrugs Are Carrier-Selective Despite Having Low Affinity for Organic Anion Transporting Polypeptides (OATPs). <strong><em>International Journal of Pharmaceutics<\/em><\/strong>, <strong>2019<\/strong>, <em>571<\/em>, 11871410. <a href=\"http:\/\/doi.org\/10.1016\/j.ijpharm.2019.118714\" target=\"_blank\" rel=\"noreferrer noopener\">http:\/\/doi.org\/10.1016\/j.ijpharm.2019.118714<\/a><\/p>\n\n\n\n<p>K\u00e4rkk\u00e4inen, J.; Gynther, M.; Kokkola, T.; Petsalo, A.; Auriola, S.; Lahtela-Kakkonen, M.; Laine, K.; Rautio, J.; Huttunen, K. M. Structural Properties for Selective and Efficient L-Type Amino Acid Transporter 1 (LAT1)- Mediated Cellular Uptake. <strong><em>International Journal of Pharmaceutics<\/em><\/strong>, <strong>2018<\/strong>, <em>544<\/em> (1), 91-99. <a href=\"http:\/\/doi.org\/10.1016\/j.ijpharm.2018.04.025\" target=\"_blank\" rel=\"noreferrer noopener\">http:\/\/doi.org\/10.1016\/j.ijpharm.2018.04.025<\/a><\/p>\n\n\n\n<p>Huttunen, K. M.; Huttunen, J.; Aufderhaar, I.; Gynther, M.; Denny, W. A.; Spicer, J. A. L-Type Amino Acid Transporter 1 (LAT1)- Mediated Targeted Delivery of Perforin Inhibitors. <strong><em>International Journal of Pharmaceutics<\/em><\/strong>, <strong>2015<\/strong>, <em>498<\/em> (1-2), 205-216. <a href=\"http:\/\/dx.doi.org\/10.1016\/j.ijpharm.2015.12.034\" target=\"_blank\" rel=\"noreferrer noopener\">http:\/\/dx.doi.org\/10.1016\/j.ijpharm.2015.12.034<\/a><\/p>\n\n\n\n<p>Ylikangas, H.; Malmioja, K.; Peura, L.; Gynther, M.; Nwachukwu, E. O.; Lepp\u00e4nen, J.; Laine, K.; Rautio, J.; Lahtela-Kakkonen, M.; Huttunen, K. M.; Poso, A. Quantitative Insights for the Design of Compounds Recognized by L-Type Amino Acid Transporter 1 (LAT1). <strong><em>ChemMedChem<\/em><\/strong>, <strong>2014<\/strong>,<em> 9<\/em> (12), 2699-2707. <a href=\"http:\/\/dx.doi.org\/10.1002\/cmdc.201402281\" target=\"_blank\" rel=\"noreferrer noopener\">http:\/\/dx.doi.org\/10.1002\/cmdc.201402281<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>L-Type Amino Acid Transporter 1 (LAT1) is a pH and sodium independent antiporter. This heterodimeric protein complex is an essential carrier of large, neutral, aromatic, or branched L-amino acids (e.g., L-Leu, L-Phe, L-Tyr, L-Trp, L-His, L-Met, L-Ile, and L-Val) and some amino acid mimicking drugs (e.g., L-dopa, gabapentin, baclofen, and melphalan). LAT1 consists of a [&hellip;]<\/p>\n","protected":false},"author":140,"featured_media":0,"parent":1047,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-1074","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.1.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>LAT1 - Drug targeting<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/sites.uef.fi\/drug-targeting\/transporters\/lat1\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LAT1 - Drug targeting\" \/>\n<meta property=\"og:description\" content=\"L-Type Amino Acid Transporter 1 (LAT1) is a pH and sodium independent antiporter. This heterodimeric protein complex is an essential carrier of large, neutral, aromatic, or branched L-amino acids (e.g., L-Leu, L-Phe, L-Tyr, L-Trp, L-His, L-Met, L-Ile, and L-Val) and some amino acid mimicking drugs (e.g., L-dopa, gabapentin, baclofen, and melphalan). LAT1 consists of a [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/sites.uef.fi\/drug-targeting\/transporters\/lat1\/\" \/>\n<meta property=\"og:site_name\" content=\"Drug targeting\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-23T08:44:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/sites.uef.fi\/drug-targeting\/wp-content\/uploads\/sites\/59\/2022\/12\/Graphical-Abstract-1024x566.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/sites.uef.fi\/drug-targeting\/transporters\/lat1\/\",\"url\":\"https:\/\/sites.uef.fi\/drug-targeting\/transporters\/lat1\/\",\"name\":\"LAT1 - Drug targeting\",\"isPartOf\":{\"@id\":\"https:\/\/sites.uef.fi\/drug-targeting\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/sites.uef.fi\/drug-targeting\/transporters\/lat1\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/sites.uef.fi\/drug-targeting\/transporters\/lat1\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/sites.uef.fi\/drug-targeting\/wp-content\/uploads\/sites\/59\/2022\/12\/Graphical-Abstract-1024x566.png\",\"datePublished\":\"2022-08-21T17:49:32+00:00\",\"dateModified\":\"2023-12-23T08:44:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/sites.uef.fi\/drug-targeting\/transporters\/lat1\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/sites.uef.fi\/drug-targeting\/transporters\/lat1\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/sites.uef.fi\/drug-targeting\/transporters\/lat1\/#primaryimage\",\"url\":\"https:\/\/sites.uef.fi\/drug-targeting\/wp-content\/uploads\/sites\/59\/2022\/12\/Graphical-Abstract.png\",\"contentUrl\":\"https:\/\/sites.uef.fi\/drug-targeting\/wp-content\/uploads\/sites\/59\/2022\/12\/Graphical-Abstract.png\",\"width\":4353,\"height\":2407},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/sites.uef.fi\/drug-targeting\/transporters\/lat1\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/sites.uef.fi\/drug-targeting\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Transporters under Our Investigation\",\"item\":\"https:\/\/sites.uef.fi\/drug-targeting\/transporters\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"LAT1\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/sites.uef.fi\/drug-targeting\/#website\",\"url\":\"https:\/\/sites.uef.fi\/drug-targeting\/\",\"name\":\"Drug targeting\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/sites.uef.fi\/drug-targeting\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LAT1 - Drug targeting","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/sites.uef.fi\/drug-targeting\/transporters\/lat1\/","og_locale":"en_US","og_type":"article","og_title":"LAT1 - Drug targeting","og_description":"L-Type Amino Acid Transporter 1 (LAT1) is a pH and sodium independent antiporter. This heterodimeric protein complex is an essential carrier of large, neutral, aromatic, or branched L-amino acids (e.g., L-Leu, L-Phe, L-Tyr, L-Trp, L-His, L-Met, L-Ile, and L-Val) and some amino acid mimicking drugs (e.g., L-dopa, gabapentin, baclofen, and melphalan). LAT1 consists of a [&hellip;]","og_url":"https:\/\/sites.uef.fi\/drug-targeting\/transporters\/lat1\/","og_site_name":"Drug targeting","article_modified_time":"2023-12-23T08:44:40+00:00","og_image":[{"url":"https:\/\/sites.uef.fi\/drug-targeting\/wp-content\/uploads\/sites\/59\/2022\/12\/Graphical-Abstract-1024x566.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/sites.uef.fi\/drug-targeting\/transporters\/lat1\/","url":"https:\/\/sites.uef.fi\/drug-targeting\/transporters\/lat1\/","name":"LAT1 - Drug targeting","isPartOf":{"@id":"https:\/\/sites.uef.fi\/drug-targeting\/#website"},"primaryImageOfPage":{"@id":"https:\/\/sites.uef.fi\/drug-targeting\/transporters\/lat1\/#primaryimage"},"image":{"@id":"https:\/\/sites.uef.fi\/drug-targeting\/transporters\/lat1\/#primaryimage"},"thumbnailUrl":"https:\/\/sites.uef.fi\/drug-targeting\/wp-content\/uploads\/sites\/59\/2022\/12\/Graphical-Abstract-1024x566.png","datePublished":"2022-08-21T17:49:32+00:00","dateModified":"2023-12-23T08:44:40+00:00","breadcrumb":{"@id":"https:\/\/sites.uef.fi\/drug-targeting\/transporters\/lat1\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/sites.uef.fi\/drug-targeting\/transporters\/lat1\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/sites.uef.fi\/drug-targeting\/transporters\/lat1\/#primaryimage","url":"https:\/\/sites.uef.fi\/drug-targeting\/wp-content\/uploads\/sites\/59\/2022\/12\/Graphical-Abstract.png","contentUrl":"https:\/\/sites.uef.fi\/drug-targeting\/wp-content\/uploads\/sites\/59\/2022\/12\/Graphical-Abstract.png","width":4353,"height":2407},{"@type":"BreadcrumbList","@id":"https:\/\/sites.uef.fi\/drug-targeting\/transporters\/lat1\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/sites.uef.fi\/drug-targeting\/"},{"@type":"ListItem","position":2,"name":"Transporters under Our Investigation","item":"https:\/\/sites.uef.fi\/drug-targeting\/transporters\/"},{"@type":"ListItem","position":3,"name":"LAT1"}]},{"@type":"WebSite","@id":"https:\/\/sites.uef.fi\/drug-targeting\/#website","url":"https:\/\/sites.uef.fi\/drug-targeting\/","name":"Drug targeting","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/sites.uef.fi\/drug-targeting\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/sites.uef.fi\/drug-targeting\/wp-json\/wp\/v2\/pages\/1074","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sites.uef.fi\/drug-targeting\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/sites.uef.fi\/drug-targeting\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/sites.uef.fi\/drug-targeting\/wp-json\/wp\/v2\/users\/140"}],"replies":[{"embeddable":true,"href":"https:\/\/sites.uef.fi\/drug-targeting\/wp-json\/wp\/v2\/comments?post=1074"}],"version-history":[{"count":2,"href":"https:\/\/sites.uef.fi\/drug-targeting\/wp-json\/wp\/v2\/pages\/1074\/revisions"}],"predecessor-version":[{"id":2157,"href":"https:\/\/sites.uef.fi\/drug-targeting\/wp-json\/wp\/v2\/pages\/1074\/revisions\/2157"}],"up":[{"embeddable":true,"href":"https:\/\/sites.uef.fi\/drug-targeting\/wp-json\/wp\/v2\/pages\/1047"}],"wp:attachment":[{"href":"https:\/\/sites.uef.fi\/drug-targeting\/wp-json\/wp\/v2\/media?parent=1074"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}